1. Home
  2. BANC vs NUVB Comparison

BANC vs NUVB Comparison

Compare BANC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banc of California Inc.

BANC

Banc of California Inc.

HOLD

Current Price

$16.77

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.44

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANC
NUVB
Founded
1941
2018
Country
United States
United States
Employees
1903
291
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
1.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BANC
NUVB
Price
$16.77
$4.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
9
Target Price
$21.39
$11.22
AVG Volume (30 Days)
2.4M
4.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.38%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.64
$182.76
Revenue Next Year
$8.03
$91.83
P/E Ratio
$17.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.52
$1.57
52 Week High
$21.61
$9.75

Technical Indicators

Market Signals
Indicator
BANC
NUVB
Relative Strength Index (RSI) 27.11 34.56
Support Level $16.28 $4.04
Resistance Level $17.40 $5.73
Average True Range (ATR) 0.61 0.32
MACD -0.19 -0.04
Stochastic Oscillator 12.15 16.38

Price Performance

Historical Comparison
BANC
NUVB

About BANC Banc of California Inc.

Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: